UK Markets open in 6 hrs 54 mins
  • NIKKEI 225

    26,991.28
    -20.05 (-0.07%)
     
  • HANG SENG

    24,289.90
    +46.29 (+0.19%)
     
  • CRUDE OIL

    87.15
    -0.20 (-0.23%)
     
  • GOLD FUTURES

    1,819.90
    -9.80 (-0.54%)
     
  • DOW

    34,168.09
    -129.64 (-0.38%)
     
  • BTC-GBP

    27,513.85
    +89.99 (+0.33%)
     
  • CMC Crypto 200

    844.52
    -11.29 (-1.32%)
     
  • Nasdaq

    13,542.12
    +2.82 (+0.02%)
     
  • ^FTAS

    4,192.70
    +53.23 (+1.29%)
     

Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • CMOPF

Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous

30-Dec-2021 / 06:00 GMT/BST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR

Dublin, Ireland - 30 December 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN) ('Cosmo') today announced that Ms. Hazel Winchester has been appointed to the position of Head of Investor Relations and will take up the position on the 10th of January, 2022.

Ms. Winchester brings almost two decades of investor relations experience. She is a seasoned IR professional who has previously held various positions for a Swiss Medtech and more recently for a SIX-listed biopharmaceutical company. Prior to that, Ms. Winchester worked with different companies in Toronto, Canada, including one which grew from small to large cap listed on the Toronto Stock Exchange and NYSE. She has served on the board of the Canadian Investor Relations Institute (CIRI) and recently joined the board of the IR Club Switzerland.

Alessandro Della Chà, CEO of Cosmo, commented: 'We have been looking for quite some time on how to fill this important role and we believe we have now found in Hazel the right person. I trust she will help us strengthen the relationship with investors at this very important moment in the history of Cosmo'.

Cosmo further announced that Mr. Stefano Selva, current CSO, has resigned from Cosmo for personal reasons with effect from the 31st of December 2021. Given the structure and the organization of the R&D Department, the Company does not plan to immediately fill the position.

Calendar

Full Year Results 2021

March 31, 2022

Annual General Meeting 2022

May 27, 2022

Half Year Results 2022

July 29, 2022

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo develops and manufactures products which are distributed globally including Lialda(R) and Uceris(R)/Cortiment(R). Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius(TM), its artificial intelligence device, which uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website:
www.cosmopharma.com

Contact
Niall Donnelly, CFO
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com


End of ad hoc announcement

Language:

English

Company:

Cosmo Pharmaceuticals N.V.

Riverside 2, Sir John Rogerson's

Dublin 2 Dublin

Ireland

Phone:

+ 353 1 817 0370

E-mail:

info@cosmopharma.com

Internet:

https://www.cosmopharma.com/

ISIN:

NL0011832936

Listed:

SIX Swiss Exchange

EQS News ID:

1263320


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting